[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100350139":3},{"organization":4,"outcomesModule":7,"designInfo":16,"detailedDescription":15,"studyPopulation":15,"armGroups":22,"interventions":28,"overallOfficials":15,"centralContacts":33,"locations":38,"responsibleParty":141,"collaborators":15,"id":143,"slug":15,"hasResults":144,"nctId":145,"briefTitle":146,"officialTitle":146,"acronym":15,"eligibilityCriteria":147,"healthyVolunteers":144,"sex":148,"minAge":149,"maxAge":15,"enrollmentInfo":150,"targetDuration":15,"studyType":153,"phases":154,"briefSummary":156,"conditions":157,"keywords":159,"overallStatus":82,"whyStopped":15,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":173},{"fullName":5,"class":6},"Vanda Pharmaceuticals","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":15,"otherOutcomes":15},[9,13],{"measure":10,"description":11,"timeFrame":12},"Safety and tolerability of trichostatin A measured by spontaneous reporting of adverse events (AEs)","Measured by spontaneous reporting of adverse events (AEs)","Up to 24 months",{"measure":14,"description":15,"timeFrame":12},"Dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of trichostatin A",null,{"allocation":17,"interventionModel":18,"interventionModelDescription":15,"primaryPurpose":19,"observationalModel":15,"timePerspective":15,"maskingInfo":20},"NA","SINGLE_GROUP","TREATMENT",{"masking":21,"maskingDescription":15,"whoMasked":15},"NONE",[23],{"label":24,"type":25,"description":15,"interventionNames":26},"Trichostatin A","EXPERIMENTAL",[27],"Drug: Trichostatin A",[29],{"type":30,"name":24,"description":31,"armGroupLabels":32,"otherNames":15},"DRUG","Intravenous Infusion",[24],[34],{"name":5,"role":35,"phone":36,"phoneExt":15,"email":37},"CONTACT","202-734-3400","clinicaltrials@vandapharma.com",[39,53,63,72,81,93,102,109,118,125,134],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":15},"Vanda Investigational Site","WITHDRAWN","Washington D.C.","District of Columbia","20007","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-77.03637,38.89511,{"lat":51,"lon":50},{"facility":40,"status":54,"city":55,"state":56,"zip":57,"country":45,"countryCode":46,"cosmosGeoPoint":58,"geoPoint":62,"contacts":15},"COMPLETED","Lafayette","Indiana","47905",{"type":48,"coordinates":59},[60,61],-86.87529,40.4167,{"lat":61,"lon":60},{"facility":40,"status":41,"city":64,"state":65,"zip":66,"country":45,"countryCode":46,"cosmosGeoPoint":67,"geoPoint":71,"contacts":15},"Hackensack","New Jersey","07601",{"type":48,"coordinates":68},[69,70],-74.04347,40.88593,{"lat":70,"lon":69},{"facility":40,"status":54,"city":73,"state":74,"zip":75,"country":45,"countryCode":46,"cosmosGeoPoint":76,"geoPoint":80,"contacts":15},"Seattle","Washington","98109",{"type":48,"coordinates":77},[78,79],-122.33207,47.60621,{"lat":79,"lon":78},{"facility":40,"status":82,"city":83,"state":15,"zip":15,"country":84,"countryCode":85,"cosmosGeoPoint":86,"geoPoint":90,"contacts":91},"RECRUITING","Biała Podlaska","Poland","PL",{"type":48,"coordinates":87},[88,89],23.11652,52.03238,{"lat":89,"lon":88},[92],{"name":5,"role":35,"phone":36,"phoneExt":15,"email":15},{"facility":40,"status":82,"city":94,"state":15,"zip":15,"country":84,"countryCode":85,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"Katowice",{"type":48,"coordinates":96},[97,98],19.02173,50.2597,{"lat":98,"lon":97},[101],{"name":5,"role":35,"phone":36,"phoneExt":15,"email":15},{"facility":40,"status":54,"city":103,"state":15,"zip":15,"country":84,"countryCode":85,"cosmosGeoPoint":104,"geoPoint":108,"contacts":15},"Krakow",{"type":48,"coordinates":105},[106,107],19.93658,50.06143,{"lat":107,"lon":106},{"facility":40,"status":82,"city":110,"state":15,"zip":15,"country":84,"countryCode":85,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"Opole",{"type":48,"coordinates":112},[113,114],17.92604,50.67119,{"lat":114,"lon":113},[117],{"name":5,"role":35,"phone":36,"phoneExt":15,"email":15},{"facility":40,"status":54,"city":119,"state":15,"zip":15,"country":84,"countryCode":85,"cosmosGeoPoint":120,"geoPoint":124,"contacts":15},"Skorzewo",{"type":48,"coordinates":121},[122,123],17.97006,54.16909,{"lat":123,"lon":122},{"facility":40,"status":82,"city":126,"state":15,"zip":15,"country":84,"countryCode":85,"cosmosGeoPoint":127,"geoPoint":131,"contacts":132},"Warsaw",{"type":48,"coordinates":128},[129,130],21.01178,52.22977,{"lat":130,"lon":129},[133],{"name":5,"role":35,"phone":36,"phoneExt":15,"email":15},{"facility":40,"status":54,"city":135,"state":15,"zip":15,"country":84,"countryCode":85,"cosmosGeoPoint":136,"geoPoint":140,"contacts":15},"Wroclaw",{"type":48,"coordinates":137},[138,139],17.03006,51.10286,{"lat":139,"lon":138},{"type":142,"investigatorFullName":15,"investigatorTitle":15,"investigatorAffiliation":15,"oldNameTitle":15,"oldOrganization":15},"SPONSOR","100350139",false,"NCT03838926","Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies","Inclusion Criteria:\n\n* Subject is ≥ 18 years at the time of signing informed consent;\n* Confirmed malignant hematologic disease or lymphoid malignancy that has relapsed or is refractory to standard therapy and has exhausted all available therapies;\n* Presence of measurable or evaluable disease;\n* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2;\n* Contraceptives or other approved avoidance of pregnancy measures\n\nExclusion Criteria:\n\n* Allogeneic stem cell transplant recipient presenting with graft versus host disease (GVHD) either active or requiring immunosuppression;\n* Concomitantly taking anti-cancer therapy (bisphosphonates are permitted);\n* Undergone major surgery ≤ 2 weeks prior to starting study drug;\n* Evidence of mucosal or internal bleeding;\n* Impaired cardiac function or conduction defect;\n* Concurrent severe and\u002For uncontrolled medical conditions","ALL","18 Years",{"count":151,"type":152},42,"ESTIMATED","INTERVENTIONAL",[155],"PHASE1","The aim of this study is to investigate the safety and tolerability of trichostatin A in individuals with relapsed or refractory hematologic malignancies.",[158],"Relapsed or Refractory Hematologic Malignancies",[160,161,162,163],"Hematologic","Malignancies","Cancer","Blood","2026-03-12",{"date":166,"type":167},"2026-03-16","ACTUAL",{"date":169,"type":167},"2018-09-27",{"date":171,"type":152},"2027-12",{"name":5,"class":6},11]